Plain language summary of the CARTITUDE-1 study of ciltacabtagene autoleucel for the treatment of people with relapsed or refractory multiple myeloma

• Published in: Future oncology (London, England) Vol. 19; no. 18; pp. 1235 - 1247
• Main Authors: Berdeja, Jesus G, Cohen, Adam D, Martin, Thomas, Madduri, Deepu, Pacaud, Lida, Jagannath, Sundar
• Format: Journal Article
• Language: English
• Published: England Future Medicine Ltd 01.06.2023
• Subjects: BCMA; CAR-T; chimeric antigen receptor-T cell; cilta-cel; ciltacabtagene autoleucel; clinical trial; Immunotherapy; lay summary; multiple myeloma; relapsed/refractory multiple myeloma; clinical trial; relapsed/refractory multiple myeloma; cilta-cel; multiple myeloma; CAR-T; Immunotherapy; chimeric antigen receptor-T cell; BCMA; ciltacabtagene autoleucel; lay summary

This is a summary of a clinical study called CARTITUDE-1. This study tested the anti-cancer chimeric antigen receptor-T cell (CAR-T) therapy ciltacabtagene autoleucel, abbreviated as cilta-cel, in people with multiple myeloma, a cancer that affects a specific type of blood cell called plasma cells....